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1. Introduction
In the present paper, we will review the available
evidence on the prognosis of the acute variceal hemor-
rhage. The aim of this review is to provide some clues
that may help to understand why none of the available
predictive models in this setting is routinely used in
clinical practice, and to identify new ways to improve
our current prognostic tools. For this purpose, we will
cover first some theoretical aspects that may serve as a
framework to evaluate a prognostic model. In the sec-
ond part of the paper, specific issues about the current
knowledge of the prognosis of the acute bleeding will
be revised.
2. Prognostic tools and clinical utility
Prognostic models are commonly regarded as more
or less complex tools for providing clinicians with 3
different valuable uses: they can help physicians take
difficult clinical decisions (such as ordering aggres-
sive therapies in selected patients) [1]; select uniform
groups for clinical trials [2]; or inform patients and
their entourage about the odds of different outcomes
in a specific situation [3]. Therefore, prognostic mod-
els are most likely to be useful for clinicians in situa-
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tions in which “decision making is complex, when the
clinical stakes are high or when there are opportunities
to achieve cost savings without compromising patient
care” [4]. The clinical scenario of an acute variceal
bleeding clearly meets these criteria. However, none
of available models in acute variceal bleeding is rou-
tinely used, and currently all patients receive the same
treatment, regardless of their baseline estimated risk of
complications.
The reasons for this situation are diverse. Several
authors [5,6] have suggested different frameworks to
evaluate the value of a given prognosticmodel (or clini-
cal decision rule) to try to understandwhy most will not
found a place in patient care. The characteristics that
make a prognostic model clinically useful have been
described by some authors [7] as relevance, validity and
work to access. Besides, a prognostic tool that meets
these criteria should proof its utility in a specific clini-
cal context, helping doctors to inform specific clinical
decisions. Finally, even if a prognostic model is valid,
relevant, easy to use and informed by the clinical con-
text, it may not be accepted by clinicians at the point of
care for a variety of reasons. We will examine all these
features in turn (see summary in Table 1).
2.1. Validity
For a model to be accepted by clinicians, it should
have proven to be accurate in predicting the outcome
of interest. The prognostic rule should rarely fail to
predict an event that will occur (low false negative rate)
and seldom predict it when it will not occur (low false
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Table 1
Desirable features of a clinically useful prognostic model (Adapted from Ebell) [6]
1. Validity The model should have been proven its accuracy in predicting the outcome, ideally in a large test
set independent from the cohort from which the model was derived
2. Relevance The model should address a clinical important (severe and/or frequent) outcome and its use should
directly help improving patient care, not just diagnostic or prognostic accuracy
3. Accessibility It should be easy for clinicians to obtain all necessary data and to calculate the model’s prediction
for an individual patient
4. Applicability The design of the model should be based on the clinical scenario in which it will be eventually used
in daily practice
5. Acceptability The model has been proven to be valid, is readily applied at the point of care, its logical structure
is apparent for the non-statistician and its predictions make sense to the clinicians who will rely on
them
positive rate). This would allow the prognostic model
to have a desirable impact on patient’s care in terms
of safety (no high-risk patients would be spared from
necessary interventions) and efficiency (no low-risk pa-
tients would be selected to undergo unnecessary proce-
dures). Moreover, these error rates should be checked
on a large independent test set, ideally in different time
and place, and using widely accepted inclusion criteria
and definitions. This might help convincing clinicians
that model predictions derived from a specific cohort
can be safely and efficiently used in their own patients.
For the case of acute variceal bleeding, very few stud-
ies have proven their validity and generality using this
standards [8–10].
2.2. Relevance
To be relevant for a physician, the prognostic model
should be able to predict an outcome that is clinically
important in terms of severity and/or frequency of the
condition. Besides, in order to gain acceptance from
practitioners, the model should demonstrate that its use
is able to improve patient-oriented outcomes (e.g., sur-
vival, time free of severe complications – such as re-
bleeding, for instance- or symptoms) and/or the use of
available resources in a real-world situation, than mere-
ly allowing accurate predictions. This sort of studies,
whichwould indeed require considerable resources, are
considered by some to be as necessary for prognos-
tic models as phase 3 randomized controlled trials for
drugs [11].
2.3. Work to access
It should be simple for clinicians to obtain all neces-
sary data and to calculate the model’s prediction for an
individual patient. Those models with a small number
of variables (i.e., that are parsimonious), ideally col-
lected at patient’s bedside, would be more easily ac-
cepted than other models requiring more time and/or
effort to acquire the needed inputs for the model. Sim-
ilarly, models for which predictions take the form of
printed trees [10] or clinical algorithm [12], will prob-
ably be used more often than those requiring access to
computers to make complex calculations [13].
2.4. Clinical context
The design of a prognostic model should be based
on the clinical scenario in daily practice in which it will
be eventually used. To fully understand this point, a
threshold model of medical decision making has been
proposed, which identifies 3 actions based on the re-
sults of a decision support tool (such as a prognostic
model) [14] (Fig. 1):
– identify a group of patients who need no further di-
agnostic/prognostic work-up because the outcome
of interest is ruled out,
– identify a group of patients who need no further
diagnostic/prognostic work-up because the risk of
outcome is so high that empirical therapy is justi-
fied, and
– identify a group of patients who would require
further evaluation because the estimated risk is not
as certain as in the two previous categories and a
safe decision cannot be made with the available
information.
Taking the clinical context into account in the de-
sign of prognostic tools means that the choice of cut-
off points for risk categories (low, intermediate, high)
should be informed by these actions in the specific clin-
ical context in which they will be used, rather than sim-
ply by maximizing statistically relevant, but clinical-
ly meaningless criteria (such as sensitivity, specificity
or the area under the receiver operating characteristics
curve). All too often, the latter set of criteria is favored
when designing and reviewing prognostic studies, lead-
S. Augustin et al. / Prognostic evaluation of patients with acute variceal bleeding 157
Fig. 1. Threshold model of medical decision making illustrating three different clinical and research approaches in acute variceal bleeding
according to potential cut-off points of 6-week mortality based on available knowledge on the efficacy of current treatments and prognostic
tools [9,10,38].
ing to the publication of tools that look valid and rel-
evant on paper, but result unhelpful in the context of
real clinical decisions. If the low-risk patients have
not a low-enough risk to rule out the outcome, and the
high-risk patients are not at high-enough risk to justify
empiric therapy, the prognostic model would be clini-
cally useless because in every case the physician would
need additional confirmatory evidence to act according
to the prediction, regardless of its accuracy.
2.5. Acceptability
A prognostic model may have been shown to be
valid, relevant, easy to use and informed by the clinical
context, and yet not be accepted for practitioners. Be-
sides hypothetical economic incentives or medico-legal
concerns, which are beyond the scope of these analysis,
it has been shown that physicians may reject an specific
prognostic model for different reasons [15]:
– Themodel’s structuremight not be apparent and/or
its predictions might not make sense to the clini-
cians who will rely on them. Classification trees
nicely resemble the algorithmic approach to deci-
sion making [10], and would be generally favored
in front of “black box” models such as artificial
neural networks, which structure is obscure to the
clinician [16].
– The model does not take into account all data that
clinicians think are relevant in the patient situation.
In this case, the parsimony that is consider desir-
able by the researcher in order to make the prog-
nostic tool easy to use is regarded as a limitation
by the practitioner.
– Some models require extensive interaction with
computers or hand-held devices, which might be
considered inappropriate in front of the patient.
– Finally, some physicians think that the use of such
tools deprives the clinician of the opportunity to
reason independently.
As seen, the physician’s attitude towards a specific
prognostic tool might be uncertain at the first stages
of its design, but is critically important and must be
considered when developing and updating a predictive
model for clinical use.
In summary, for the case of the acute variceal hem-
orrhage, it should be remarked that the so-called prog-
nostic models should not be regarded as “prognostic”
in the sense of forecasting future events, as these tools
are not accurate enough for this purpose. As we will
see in the following sections, what these tools are well-
suited for is to retrospectively classify patients into cat-
egories or strata of individuals sharing a specific com-
bination of clinical characteristics and comparable out-
comes. In the specific context of the acute bleeding
episode, this feature may be of great use for clinical
and research purposes to identify target subpopulations
in trials evaluating risk-based strategies.
3. Time frame of the acute bleeding
According to the last international consensus work-
shop of Baveno on portal hypertension, the time frame
for the acute bleeding episode should be 120 hours
(5 days) [17]. Therapeutic measures started at day 6
and thereafter are considered to be aimed at preventing
the recurrence of bleeding, and are regarded as sec-
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(a) (b)
Fig. 2. Survival curve of patients after a variceal hemorrhage and clustering of mortality in the earlier 6-week period in a cohort study of untreated
patients* (a), with permission [19]; and in a therapeutic study of patients randomized to early TIPS or combined pharmacologic plus endoscopic
therapy (b), with permission of the author [39]. *Patients in the study did not receive specific hemostatic therapy, except for 13% of patients who
received vasopressin during the acute bleeding.
ondary prophylaxis (or elective treatment) of variceal
bleeding. Within this 5-day frame, the most relevant
outcome by consensus has been failure to control bleed-
ing (or treatment failure). This is a composite end-
point which includes death, persistence of uncontrolled
bleeding and/or occurrence of a rebleeding episode in-
tense enough to prompt a change of therapy. After day
5, the clinical event that is most often considered the
endpoint of interest is the occurrence of a significant
rebleeding episode.
The 6-week period following the index bleeding
episode is widely used in therapeutic trials and prog-
nostic studies, although it has been only tangentially
addressed in guidelines [17,18]. The identification of
a critical 6-week period frame after an acute variceal
bleedingwas originally published in 1981 [19]. In their
seminal paper, Graham and Smith showed that the in-
cidence of mortality, rebleeding, and other complica-
tions, increases sharply during the first 6 weeks and
then stabilize, returning afterwards to the level previous
to the bleeding episode (Fig. 2a). This observation of
clustering of complications in the 6weeks following the
acute episode has been constantly reproduced in many
studies ever since. Even the improvement in the man-
agement of these patients, with a 4-fold reduction in
mortality in the past 3 decades [20], has not altered this
dynamic (Fig. 2b) [21], which can therefore be regard-
ed as the single most robust observation in the progno-
sis of the acute variceal bleeding. This consistent dy-
namic, along with the difficulty of identifying a single
cause of death after the bleeding (hemorrhage vs. liver
failure vs. renal failure, etc.), has led by consensus to
the pragmatical assumption that any death occurring in
the 6-week period following a variceal bleeding should
be considered as secondary to the acute hemorrhagic
episode [22].
4. What factors? Under what therapies?
Although it may be seem obvious, it is worth re-
marking that when addressing the prognosis of an acute
variceal bleeding, we are implicitly referring to the ef-
ficacy of the therapies being used. There is no point to
separate this two concepts in practice. The same should
be considered when comparing factors across different
studies. A given prognostic factor could be relevant un-
der a particular treatment approach, and loose its prog-
nostic value if therapy is changed. An example could
be the value as risk factor of the observation of active
bleeding at the initial endoscopy,which may vary great-
ly on whether the patients in the study were receiving
an effective vasoactive drug or not. Therefore, in order
to interpret adequately the current clinical value of a
prognostic factor, it is essential to take into account the
treatment approach used in the studies from were its
value is derived.
This evident influence of efficacy of treatments on
prognosis is themain reasonwhy the predictive value of
prognostic models may change over time, and stresses
the need to update our prognostic tools as therapeutic
approaches are beingmodified. In acute variceal bleed-
ing, this becomes especially relevant because as the ef-
ficacy of hemostatic treatments improves, the incidence
of treatment failure decreases and so does the relative
weight of variables strictly related to the intensity of the
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acute hemorrhage (e.g., shock, active bleeding, trans-
fusion requirements, etc.). Consequently, it is likely
that other variables (such as infection or worsening of
renal failure) become more relevant.
5. 5-day failure vs. 6-week mortality
Although considering a 5-day frame for the acute
bleeding greatly simplifies the design of therapeutic tri-
als (especially for the case of hemostatic therapies), we
believe that 5-day failure may not be the most adequate
endpoint to assess the prognosis after a variceal hem-
orrhage. The first problem encountered is the defini-
tion of failure to control bleeding, which is based on
an essentially subjective and prone-to-change concept
(“need to change therapy“) [17]. In fact, despite the
efforts made over the years to provide valid and objec-
tive criteria to generalize the indication of change of
therapy, consensus is still elusive.
The second problem of the 5-day failure endpoint
is that this time interval is not long enough to account
for the whole spectrum of complications related to the
bleeding episode, since some important complications
related to the bleeding episodemay requiremore time to
develop. Therefore, some interventions (mainly hemo-
static therapies) may proof to reduce 5-day failure, but
may result unable to extend their impact on harder out-
comes (6-week mortality) [23], which may imply an
overestimation of their practical value. And inversely,
other therapies able to improve 6 week survival (such
antibiotic prophylaxis, for instance [24] may fail to
proof their value if the analysis period is limited to 5
days. As a consequence and in analogy, the estimation
of prognosis at 5 days may differ significantly from that
at 6 weeks.
As an alternative, 6-week mortality shows clear ad-
vantages as endpoint of prognostic studies in acute
variceal bleeding. The first obvious advantage is that
mortality is strictly objective, and therefore exempt
from definition problems. Secondly, it comprises a
great part of treatment failures (those deaths occurring
in the first 5 days). Finally, and most importantly, it
does take into account the prognostic implications of
relevant events that tend to reveal after day 5 (worsen-
ing of liver and/or renal function, some types of infec-
tion, etc.). For all these reasons, we consider mortality
at 6 weeks as the most adequate endpoint for prognostic
studies in acute variceal bleeding.
6. Prognostic factors in acute variceal bleeding
The value of different clinical and hemodynamic
variables in determining the outcome after an acute
variceal bleeding has been the matter of a number of
studies in the past decade. Table 2 summarizes the
largest studies (N > 100 patients) published in the last
10 years evaluating the accuracy of invasive and clini-
cal variables in the prediction of outcomes in variceal
bleeding [8–10,25–27]. In order to interpret the rela-
tive value and potential clinical usefulness of the dif-
ferent studies, several considerations should be kept in
mind. Regarding the treatments being used, it should
be taken into account that the current recommended
standard of care (vasoactive drug plus endoscopic ther-
apy plus antibiotics) was applied only in two studies [9,
10]. Also, the use of some sort of validation of the
prognostic model (in the same sample or, preferably,
in an independent cohort) was lacking in half of the
studies. Finally, is important to remind that none of
the prognostic models proposed has been adopted for
routine clinical use, as stated above.
Considering only the studies depicted in Table 2,
as many as 9 variables were identified as independent
markers for rebleeding or failure to control bleeding
and 18 for early mortality. These figures give an aver-
age of 3 “new” variables reported in each new study.
This diversity is most probably due to the heteroge-
neous nature of the studies: different cohorts, different
treatments, different baseline hypothesis, which lead to
the use of different statistical approaches and the inclu-
sion of different set of variables inmultivariate analysis,
all these factors leading to diverse results. Neverthe-
less, a pragmatic grouping of the independent risk fac-
tors found in these studies could be made based on the
outcome of interest (rebleeding or mortality), and on
whether the variable informs about liver function sta-
tus, the intensity of the hemorrhage, or the occurrence
of complications related to the bleeding (Table 3).
6.1. Rebleeding/treatment failure
As seen, only in a few studies was early rebleeding
considered as a separate endpoint and analyzed inde-
pendently from mortality. The risk of early rebleeding
has been assessed in most studies together with initial
failure to control the bleeding and 5-day mortality, as
the composite endpoint 5-day failure. However, the
risk of 5-day failure has not been homogenously report-
ed across studies. This is probably due to pragmatic
difficulties concerning the definition of the endpoint, as
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Table 3
Independent prognostic factors of rebleeding/treatment failure (A) and 6-week
mortality (B) obtained from the most relevant (N > 100 patients) prognostic
studies and other therapeutic trials in acute variceal bleeding published between
2001–2010
A)
Rebleeding/treatment failure Odds ratio/hazard ratio Refs.
Baseline liver function
Child-Pugh score 1.2 28
Child-Pugh class 17.6 (C vs A), 2.7 (A/B/C) 9, 8
MELD score 1.04 27
Etiology of cirrhosis (non-alcohol) 5.0 9
Portal vein thrombosis 3.0 8
HVPG 20 mmHg 5.4 9
Intensity of hemorrhage
Active bleeding at endoscopy 2.1 8
Clot on varix 2.4 27
Transfusion volume 1.4 27
Alanine aminotransferase 1.003 8
Hemodynamic shock 4.9–5.5 9
Development of Complications
Bacterial infection 4.6–9.7 28,29,30
B)
6-week mortality∗ Odds ratio/hazard ratio Refs
Baseline liver function
Child-Pugh score 1.3 10
Albumin 0.4 8
Encephalopathy 2.4 8
Bilirrubin 1.2 8
Prothrombin level < 40% 7.9 26
MELD score 1.1 27
HCC 3.1–6.0 8,10
Intensity of hemorrhage
Active bleeding at endoscopy 7.8 31
Hematemesis 2.7 26
Transfusion volume 1.2–1.4 9,27
Development of Complications
Creatinine (baseline) 2.3 10
Infection 6.1 10
Early rebleeding 3.2–8.7 32,33
Others
Inpatients 3.6 26
Digestive cancer 4.5 26
Corticosteroids use 3.8 26
Age > 60 1.8 26
∗In Lecleire [26] the outcome was “mortality during hospitalization”.
discussed above, and especially for the case of studies
in which data were collected retrospectively.
Severity of the liver disease, estimated by the Child-
Pugh score, the Model for End-Stage Liver Disease
(MELD) score or its individuals components, has been
widely recognized as a robust independent determinant
of 5-day failure [17,34]. A complementary set of vari-
ables reflecting the intensity of the bleeding episode
(active bleeding at initial endoscopy, hemodynamic
shock, transfusion requirements) has been also iden-
tified as relevant determinants of 5-day failure, as it
could be expected from the definition of this outcome.
The prognostic value of other variables (platelet count,
etiology of cirrhosis, portal vein thrombosis) seems to
be less reproducible between studies [35].
6.2. Mortality
When classifying patients according to their estimat-
ed risk of 6-week mortality, the baseline severity of
the liver disease (mainly Child-Pugh class C) is again
the main and most constant clinical determinant across
studies [36]. The presence of hepatocellular carcinoma
(which is most of the times closely related to liver func-
tion) has been also recognized as an important factor
regarding 6-week mortality [10,36].
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As previously discussed, one of the main practical
implications of considering 6-week mortality as end-
point of prognostic studies in acute variceal bleeding
is that the relative weight of variables reflecting the in-
tensity of the hemorrhage decreases. Conversely, the
influence on outcomes of other severe complications
that may take more than 5 days to develop (such as re-
nal failure or infections) is increased. In a recent pub-
lished study by our group, development of bacterial in-
fection and renal failure were indeed key determinants
of 6-week mortality [10]. The recognition of the im-
portance of such factors may be of great clinical value,
as they are essentially potentially modifiable factors.
The development of treatment strategies aimed at pre-
venting their occurrence may have a significant impact
on outcomes after an acute variceal bleeding. To this
regard, the efficacy of the 7-day antibiotic prophylax-
is and its beneficial impact on survival may be taken
as an example [24]. Besides, the need for aggressive
management of renal dysfunction in cirrhotic patients
is currently widely encouraged [18,22], but there are
no controlled trials on the prevention or treatment of
renal dysfunction after a variceal hemorrhage.
6.3. HVPG vs. non-invasive variables and the use of
TIPS in acute variceal bleeding
The use of the hepatic venous pressure gradient
(HVPG) has proven an excellent prognostic value for
both treatment failure and mortality after an acute
variceal hemorrhage [37]. In a multicenter trial by
Monescillo et al. [31], an HVPG  20 mmHg deter-
mined in the first 48 hours allowed an early classifi-
cation of patients in two subpopulations with clearly
different outcomes. Besides, the HVPG 20 mmHg cut-
off showed a better discriminative ability than Child-
Pugh score for both treatment failure and early mortali-
ty. However, it is worth remarking that the control arm
in that study received only endoscopic sclerotherapy as
treatment of the acute episode. This may have an in-
fluence not only in terms of the comparison of efficacy
between the treatments being tested (“standard of care”
vs. early TIPS insertion), but on the external validity
(i.e., the reproducibility in different care settings) of the
proposed prognostic rule.
In fact, in a more recent study in which all patients re-
ceived combined pharmacologic plus endoscopic ther-
apy, the prognostic ability of HVPG was compared
to that of a combination of non-invasive clinical vari-
ables (Child-Pugh score, systolic blood pressure, non-
alcoholic etiology) [9]. In that study, HVPG failed
to improve the accuracy of the prognostic model built
on clinical variables, suggesting that non-invasive vari-
ables may be sufficient to adequately stratify patients
by risk in the acute episode.
In accordance with this observation, a new classi-
fication rule based on non-invasive clinical variables
was used in a recent trial to stratify patients with acute
variceal bleeding early after admission according to
the estimated risk of treatment failure [21]. Those pa-
tients with Child-Pugh class B and active bleeding at
endoscopy or Child-Pugh class C were considered to
have a higher risk and were randomized to receive ei-
ther the current standard of care or early TIPS inser-
tion. The study showed that a treatment strategy based
on early risk assessment and subsequent TIPS insertion
is highly effective. An adequate selection of patients
may help to optimize treatment and greatly improve
outcomes in acute variceal bleeding. However, in or-
der to assess the real value of TIPS and to optimize
its use in clinical practice, two key aspects ought to be
addressed. First, Child-Pugh B patients in that study
had much better outcomes than Child-Pugh C patients
(total mortality 9% vs 42%), suggesting that the selec-
tion rule of candidates could be improved. Second, the
outcomes of patients in the control arm of that study
were worse (33% 6-week mortality) than what could be
a priori expected from previous studies (8% in patients
with baseline HVPG  20 mmHg) [9]. It could be
speculated that the higher mortality in the control arm
of the early-TIPS study could be due in part to the fact
that a proportion of patients in that group underwent
sclerotherapy instead of ligation in the acute setting.
To this regard, in a more recent observational study by
our group, performed in a cohort of 162 patients with
variceal bleeding receiving the current standard of care
in the acute phase (vasoactive drugs, endoscopic lig-
ation and antibiotics), most patients selected with the
criteria used in the early-TIPS study had excellent out-
comes with standard therapy (10% 6-week mortality),
suggesting that previous criteria to identify such high-
risk patients may not be adequate [38,39]. Moreover,
a new classification rule (Child-Pugh C with baseline
creatinine  1.0) to better identify a high-risk popu-
lation in this setting was provided, in order to try to
optimize the use of TIPS in clinical practice.
In summary, the early use of covered TIPS is highly
promising and may lead to a significant change in the
management of high-risk patients with acute variceal
bleeding. However, the criteria used to select those
high-risk patients (which are based in prognostic anal-
yses) should be further refined as effectiveness of stan-
dard therapeutic approaches are being updated.
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7. Conclusions
Management of the acute variceal bleeding episode
has greatly improved over the past recent years. How-
ever, treatment failures and mortality remain high, es-
pecially in patients with poor liver function, even if the
current standard of care is carefully applied. Thera-
peutic developments and increasing knowledge in the
prognosis of this complication may allow optimization
of the management strategy of the acute bleeding in
the near future, adapting the different treatments to the
expected risk of complications for each patient. The
design of accurate and manageable prognostic tools
providing an early risk classification would facilitate
the initiation of more aggressive treatments in high-
risk patients and spare low-risk individuals unneces-
sary procedures. Current research efforts will hopeful-
ly clarify this hypothesis and help to further improve
the outcomes of this severe complication of cirrhosis.
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